Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod
(1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting
multiple sclerosis (RRMS)